As such, genetic deletion of RIP3 protects against steatosis and liver injury in both ALD and NAFLD 12, while inhibition of necroptosis through genetic deletion of MLKL or pharmacological means ameliorates steatosis and liver injury in NAFLD 25, 26. The gene discussed is MLKL; the disease is metabolic dysfunction-associated steatotic liver disease.